SummaryRMgm-656
|
||||||||
*RMgm-656| Successful modification | The parasite was generated by the genetic modification |
| The mutant contains the following genetic modification(s) | Gene mutation |
| Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 21899701 |
| MR4 number | |
| top of page | |
| Parent parasite used to introduce the genetic modification | |
| Rodent Malaria Parasite | P. berghei |
| Parent strain/line | P. berghei ANKA |
| Name parent line/clone | Not applicable |
| Other information parent line | no details of the parasite line are provided |
| top of page | |
| The mutant parasite was generated by | |
| Name PI/Researcher | I. Siden-Kiamos; K. Matuschewski |
| Name Group/Department | Institute of Molecular Biology and Biotechnology |
| Name Institute | Foundation for Research and Technology- Hellas |
| City | Heraklion, Crete |
| Country | Greece |
| top of page | |
| Name of the mutant parasite | |
| RMgm number | RMgm-656 |
| Principal name | MyoA absent in ookinete (Mao) |
| Alternative name | |
| Standardized name | |
| Is the mutant parasite cloned after genetic modification | Yes |
| top of page | |
| Phenotype | |
| Asexual blood stage | Not different from wild type |
| Gametocyte/Gamete | Not different from wild type |
| Fertilization and ookinete | Normal numbers of mature ookinetes are formed. Expression of MyoA was absent in mutant ookinetes. Ookinetes are devoid of motility. Oocyst production was strongly reduced |
| Oocyst | Ookinetes are devoid of motility. Oocyst production was strongly reduced |
| Sporozoite | See 'Additional remarks phenotype' |
| Liver stage | Not tested |
| Additional remarks phenotype | Mutant/mutation Protein (function) Phenotype Additional information Other mutants |
Mutated: Mutant parasite with a mutated gene| top of page | |||||||||||||||||||||||||||
| Details of the target gene | |||||||||||||||||||||||||||
| Gene Model of Rodent Parasite | PBANKA_1355700 | ||||||||||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_1342600 | ||||||||||||||||||||||||||
| Gene product | myosin A | ||||||||||||||||||||||||||
| Gene product: Alternative name | MyoA | ||||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||||||||||
| Short description of the mutation | 'promoter-swap' mutant; the promoter of myosin A replaced by the promoter of ama1 (PBANKA_091500) | ||||||||||||||||||||||||||
| Inducable system used | No | ||||||||||||||||||||||||||
| Short description of the conditional mutagenesis | Not available | ||||||||||||||||||||||||||
| Additional remarks inducable system | |||||||||||||||||||||||||||
| Type of plasmid/construct | Plasmid single cross-over | ||||||||||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||||||||||
| Restriction sites to linearize plasmid | HpaI | ||||||||||||||||||||||||||
| Selectable marker used to select the mutant parasite | pbdhfr | ||||||||||||||||||||||||||
| Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||||
| Selection (negative) procedure | No | ||||||||||||||||||||||||||
| Additional remarks genetic modification | For the 'promoter swap' construct a 1.1 kb 3’ deleted PbMyoA fragment was amplified with primers MyoAfor-BamHI and MyoArev-NdeI. In addition, a 1.3 kb region covering the PbAMA1 promoter was amplified using the primers AMA1for and AMA1rev. A single cross-over event at the site of linearization within the 5' region of the MyoA open reading frame leads to an upstream copy that contains the endogenous promoter before a 3' deleted, non-functional MyoA copy. Downstream of this copy is the positive selectable marker and a functional copy consisting of a full-length MyoA allele, which is under the control of the ama1 promoter. | ||||||||||||||||||||||||||
| Additional remarks selection procedure | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||||